Therefore, sensitizing gliomas with MNK1 inhibitors prior to e.g. temozolomide treatment may be particularly effective in glioma patients carrying CDH1 variants affecting WNT/β-catenin signaling. Here, CDH1 is linked to central nervous system cancer.